AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03089463 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Observation
Description: The primary objective is to employ the measurements of neuropathy, micro/macro-perfusion, and biomechanics of the foot mainly tissue stiffness and plantar pressure to determine the vulnerability of foot to mechanical trauma and ulceration. From the data collected it is proposed that a prognostic risk stratification system will be developed based on the range of parameters collected to identify those that are at highest risk of ulceration incident. Those that are classed as high risk are to be sub-stratified to increase the accuracy of the system in predicting ulceration. This will allow a patient-specific approach to be taken in the prevention of ulcers by providing adequate information to predict ulceration incident.
Study NCT04746469 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed automated phone call
Description: Cipher provides automated phone calls to patients; in this case the script for Cipher was modified to provide patients a reminder to return FIT kits, allow patients to request a new kit in case they need a replacement, and to allow patients to provide information if they already completed CRC screening
Study NCT02359461 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combination pulsatile Stendo3
Study NCT01905150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-FLIP
Description: G-FLIP is a combination of Low Doses of Gemcitabine, Fluorouracil \[5FU\], Leucovorin, Irinotecan, and Oxaliplatin
Study NCT01905150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-FLIP
Description: G-FLIP is a combination of Low Doses of Gemcitabine, Fluorouracil \[5FU\], Leucovorin, Irinotecan, and Oxaliplatin
Study NCT02359461 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Combination pulsatile Stendo3
Study NCT04343352 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: implementation of mobile epilepsy training program
Description: Mobile epilepsy training program will be applied to the application group for 3 months.~The mobile epilepsy training program developed within the scope of the thesis will be introduced to the parents in the application group and the participants will be uploaded to their phones via computer, and the use of the program will be taught in practice. In addition, the participants in the application group will be informed that the mobile epilepsy training program is not open to everyone during the research process, only the application group can use it. After the work is completed, the mobile application control group will be installed on the phones of the parents via computer, their application will be taught and applied.
Study NCT01954589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-462206 5 mg
Study NCT01954589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-462206 25 mg
Study NCT01954589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-462206 100mg
Study NCT01954589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-462206 200mg
Study NCT01954589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-462206 400mg
Study NCT01954589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-462206 1000 mg
Study NCT01954589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-462206 1500mg
Study NCT01954589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Almorexant 400mg
Study NCT01954589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02532504 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CBT
Description: 8 sessions of CBT based intervention called change your life with seven sheets of paper by Prof. Chris Williams. These sheets cover key skills of CBT that are;~1. Five Areas vicious circle~2. Bad thought spotter~3. Amazing Bad thought Busting Programme (ABTPB)~4. Easy 4 Step plan~5. Things you do that mess you up/Confidence sheet~6. Happy List/ Things you do that boost how you feel sheet~7. Planner and Review sheets
Study NCT01905150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-FLIP-DM
Description: G-FLIP-DM is low doses of Gemcitabine, Fluorouracil \[5FU\], Leucovorin, Irinotecan, Oxaliplatin, Docetaxel and Mitomycin C
Study NCT01905150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-FLIP-DM
Description: G-FLIP-DM is low doses of Gemcitabine, Fluorouracil \[5FU\], Leucovorin, Irinotecan, Oxaliplatin, Docetaxel and Mitomycin C
Study NCT01905150 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: High dose of Vitamin C, used in combination with G-FLIP and then G-FLIP-DM
Study NCT00703300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study NCT00703300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Given IV
Study NCT00703300 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00703300 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies
Study NCT02157519 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Application Intervention
Description: Participants assigned to the intervention group will receive the mobile application intervention for approximately three months after enrollment. The mobile app intervention will consist of completing an initial chemotherapy treatment plan, responding to weekly assessments regarding symptoms, side effects, and medication adherence, as well as receiving personalized feedback about responses. The results from patient surveys within the app will also be transmitted in real-time to the participants' oncology clinicians via a HIPAA-compliant, secure email.
Study NCT02238730 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrabrief Right Unilateral
Description: The first six electroconvulsive therapy sessions using ultrabrief (0.25 ms) right unilateral electroconvulsive therapy
Study NCT02238730 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Brief Pulse Bitemporal
Description: The first six electroconvulsive therapy sessions using brief pulse (0.5 ms) bitemporal electroconvulsive therapy
Study NCT01749956 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Study NCT01749956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Study NCT01749956 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Abdominoperineal or low anterior resection with total mesorectal excision, per standard treatment guidelines
Study NCT01749956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX6
Study NCT04548544 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training for Awareness, Resilience, and Action (TARA)
Description: This will be a 12-week group meditation training - Training for Awareness, Resilience, and Action (TARA)
Study NCT03410004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Chidamide 30mg orally BIW. Treatment cycles are repeated every 4 weeks.
Study NCT03749317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVIEW-1201
Description: IVIEW-1201; QID; one drop per eye, four times per day (QID) for 7 days
Study NCT03749317 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drug; QID; one drop per eye, four times per day (QID) for 7 days
Study NCT03947697 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Neuromuscular Electrical Stimulation (Sensory)
Description: Group will receive Electrical Stimulation up to sensory level
Study NCT03947697 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation
Description: Group will receive Electrical Stimulation up to maximum tolerable level
Study NCT03947697 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Resistance Training
Description: Group will receive exercise training.
Study NCT03947697 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Group will receive exercise training.
Study NCT04352998 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: One dose pre-workout condition
Description: one dose of a multi-ingredient pre-workout supplement
Study NCT04352998 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Two dose pre-workout condition
Description: two doses of a multi-ingredient pre-workout supplement
Study NCT04352998 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo condition
Description: one dose of a placebo
Study NCT02330289 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Normative report card
Description: Personalized visual report card describing physician's laboratory ordering pattern for prior week relative to peers as well as a link to a website tracking lab ordering for the team in real time compared to peer teams.
Study NCT02417077 — intervention group
Intervention type: OTHER
Intervention: Photographic Review
Description: Photographic review of subjects who received treatment with onabotulinumtoxinA for crow's feet lines.
Study NCT04245943 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: 18 weeks supervised strength and aerobic exercise training.
Study NCT02299089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: octreotide FluidCrystal® injection depot
Study NCT03862248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6EH³RZ
Description: New high-dose isoniazid retreatment regimen (6EH³RZ) - H 15mg/kg
Study NCT03862248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6EHR³Z
Description: New high-dose rifampicin retreatment regimen (6EHR³Z) - R 30mg/kg
Study NCT03862248 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6EHRZLfx
Description: WHO levofloxacin-strengthened regimen (6EHRZLfx)
Study NCT02586766 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Sync
Description: A 30 minute private on-on-one brief motivational interviewing intervention given during emergency department care. The goal of the intervention was to reduce and prevention youth violence using techniques to change behavior in a respectful, non-confrontational, and non-judgmental manner. This one-on one counseling approach emphasizes individual choice and responsibility and differentiates between future goals/values and current behavior
Study NCT00525590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLIADEL
Description: Resect the tumor as completely as possible. After repeated irrigation of the decompressed area demonstrates no bleeding, and care is taken not to have any foreign material enter the ventricle, up to 8 GLIADEL wafers should be placed to cover the entire surface area of the resection cavity (if possible). Slight overlapping of wafer edges is permitted. The number of wafers will be determined by the size of the tumor resection cavity. Each GLIADEL wafer contains 7.7 mg of carmustine, resulting in a dose of 61.6 mg when 8 wafers are implanted. The GLIADEL wafer is a round white to yellow disk with flat surfaces.
Study NCT05875688 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cementation Technique A
Description: * Use of adequate amount of cement.~* Prevention of wastage of cement.~* Retention of crowns for longer duration.
Study NCT05875688 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cementation Technique B
Description: * Use of Sufficient Cement Quantity.~* Keeping cement from going to waste.~* Increased time that crowns remain in place.
Study NCT03509168 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol Pfizer Brand
Description: insertion of a preoperative single dose 400 micrograms of Misoprostol Pfizer Brand placed vaginally
Study NCT03509168 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Non-insertion of Misoprostol Pfizer Brand
Description: participants in this arm will receive the standard of care which in our setting involves the use of either a tourniquet to control intraoperative blood loss especially if the fibroids are large or rarely, other interventions like oxytocin, tranexamic acid, vasopressin and occasionally not using either of the interventions.
Study NCT00380536 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-Led Health Education Class
Description: Participants will participate in group sessions once a week for 6 weeks. Sessions will focus on medical self-management, healthy behaviors, and effective use of the general medical system.
Study NCT03199352 — intervention group
Intervention type: OTHER
Intervention: RYGB hand-sewn
Description: Patients will have the RYGB anastomosis hand-sewn
Study NCT03199352 — intervention group
Intervention type: OTHER
Intervention: RYGB linear-staple
Description: Patients will have the RYGB anastomosis performed using a linear staple.
Study NCT00749398 — intervention group
Intervention type: BIOLOGICAL
Intervention: Infliximab
Description: According to local country regulations.
Study NCT03401047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Description: Subjects will receive graded doses of transdermal estradiol patches for up to 7 days. Blood estradiol tests will be performed daily, and the number of estradiol patches used will be adjusted to maintain serum estradiol levels of 250-400 pg/ml. Estradiol is a natural hormone.
Study NCT00994305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine
Description: 600 mg bid po 0-7 PO
Study NCT00994305 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: control
Description: No treatment: standard care provided. No N-acetylcysteine administration.
Study NCT03506048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Given orally once daily continuously
Study NCT01666483 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: micro-laparoscopy
Description: M-LPS hysterectomy was performed through one optical trans-umbilical 5 mm trocar and three 3 mm sovra-pubic ancillary ports. A 5 mm 0° endoscope and 3 mm laparoscopic instruments were utilized, choosing among graspers, cold scissors, suction/irrigation and bipolar coagulator.
Study NCT01666483 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoendoscopic single site surgery
Description: LESS hysterectomy was performed through a multi-channel single trocar inserted in the umbilicus using an open technique (1.5-2 cm cutaneous incision), as previously reported. Intra-abdominal visualization was obtained with a 0° 5-mm telescope with a flexible tip. Working straight 5-mm instruments were inserted into the remaining 2 ports, choosing among graspers, cold scissors, suction/irrigation bipolar coagulator and a multifunctional versatile laparoscopic device, which grasps, coagulates and transects simultaneously. In order to prevent clashing between instruments and surgeon's hands and to facilitate surgical manoeuvres, the combination of one 33 cm-long instrument with a 43 cm-long instrument was adopted. The umbilical fascia was closed with a figure-of-eight 0-Vicryl.
Study NCT04319393 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: The CBT intervention was carried out through six two-hour sessions over a month. The intervention group was divided into three subgroups of 18 to 19 nurses each. It was required for each subgroup to attend two CBT sessions to complete the intervention.~The CB therapist followed the same structure in the delivery of each CBT session. The CBT session was delivered in five modules: generating objectives and outcomes, enhancing self-esteem and interpersonal relationships, changing beliefs regarding symbolic mortality, and changing attitudes regarding death anxiety. The first session began with highlighting the objectives of the CBT. Then, a detailed presentation of the intervention modules was provided to the nurses with integration of CBT exercises, including cognitive restructuring, graded exposure, mindfulness meditation, interpersonal skills training, and activity scheduling
Study NCT02343224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alpha-2b
Description: PEG-Intron 1mcg/kg/dose weekly through an injection under the skin on the same day each week
Study NCT03573635 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Supratube
Description: Aspiration of orotracheal secretions with supratube device
Study NCT03573635 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Reference
Description: Usual aspiration with any other device
Study NCT02623712 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: More Frequent Surveillance Strategy
Description: Chest CT scans to be repeated at 3, 6, 12 and/or 24 months, depending on patient risk factors and nodule size and attenuation (density)
Study NCT02623712 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Less Frequent Surveillance Strategy
Description: Chest CT scans to be repeated at 3, 6, 12 and/or 24 months, depending on patient risk factors and nodule size and attenuation (density). Overall, participants in the less frequent arm are expected to undergo 30% fewer surveillance imaging tests.
Study NCT01663402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Alirocumab administered as SC injection of 1 mL in the abdomen or thigh with a disposable auto-injector.
Study NCT01663402 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to alirocumab administered as a SC injection of 1 mL in the abdomen or thigh with a disposable auto-injector.
Study NCT01663402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMT
Description: Statins (atorvastatin or rosuvastatin) at stable maximal tolerated dose of statin with or without other LMT as clinically indicated.
Study NCT01663402 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LMT
Description: Statins (atorvastatin or rosuvastatin) at stable maximal tolerated dose of statin with or without other LMT as clinically indicated.
Study NCT02360514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hantavax injection
Description: Intramuscular or hypodermic injection of 0.5ml per time twice at interval of 1 month for adults. For more immune, inoculate muscle or subcutaneous once mor 12 months after the completion of the initial immune
Study NCT03319771 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treadmill Walking Exercise Training
Description: 12-weeks of supervised, progressive treadmill walking exercise training
Study NCT03319771 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching-and-toning Exercise Training
Description: 12-weeks of supervised, stretching-and-toning exercise training
Study NCT02347046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FYU-981, (Oral single dosing)
Description: FYU-981, (Oral single dosing)
Study NCT02740842 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal behavioral change communication
Description: This arm includes home visits to mothers with infants and young children. Frontline health workers will counsel and support mothers in relation to breastfeeding and complementary feeding practices
Study NCT02740842 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mass media
Description: A nationwide mass media campaign of TV and radio spots on infant and young child feeding practices will be aired in 2011, 2012 and 2013. All intervention arms will be exposed to this campaign.
Study NCT02740842 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mass media
Description: A nationwide mass media campaign of TV and radio spots on infant and young child feeding practices will be aired in 2011, 2012 and 2013. All intervention arms will be exposed to this campaign.
Study NCT03148262 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Comfort Flo system
Description: The Comfort Flo system will be used for the high flow nasal cannula during procedural sedation
Study NCT03148262 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: The Salter nasal cannula
Description: A Salter nasal cannula will be used at 4L/ minute during the procedural sedation.
Study NCT01774591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azilsartan medoximil
Description: All subjects were randomized to 80mg azilsartan medoxomil (azilsartan) daily or placebo and followed for six months.
Study NCT01774591 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All subjects were randomized to 80mg azilsartan medoxomil (azilsartan) daily or placebo and followed for six months.
Study NCT01159574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 40mg will be given on days 1, 8, 15, 22 of a 28-day cycle
Study NCT01159574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clarithromycin
Description: orally at a dose of 500 mg twice a day on days 1-28 of a 28 day cycle
Study NCT01159574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: orally 4mg daily for days 1-21 of each 28 day cycle
Study NCT01909700 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single Incision Mesh
Description: Single Incision Mesh is implanted for pelvic floor reconstruction
Study NCT02991274 — intervention group
Intervention type: PROCEDURE
Intervention: genomic testing of T790M mutation
Description: patients will need to have genomic testing of T790M mutation at hospital laboratories and in central laboratory.